Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances
- PMID: 38087716
- DOI: 10.1016/j.blre.2023.101161
Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances
Abstract
Idiopathic multicentric Castleman disease (iMCD) is a rare disease, and it is likely underdiagnosed because of the heterogeneity of clinical manifestations and laboratory findings. While the disease leads to significant morbidity and mortality, its causes are not yet fully elucidated. There have been significant advances in diagnosis and treatment of iMCD in the past decade, including the approval of the anti-IL-6 antibody siltuximab. In this review, we provide an update of the many new developments and publications surrounding iMCD.
Keywords: IL-6; Idiopathic multicentric Castleman disease; Siltuximab.
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Recordati Rare Diseases Inc. is the manufacturer of siltuximab. Within the past 12 months, Prof. Frits van Rhee was an Advisory Board member of the following companies/organizations: Adicet Bio, Bristol Myers Squibb, Castleman Disease Collaborative Network, EUSA Pharma, GlaxoSmithKline, Janssen Pharmaceuticals, Inc., Kite Pharma and Secura Bio. Dr. Evan Lang has no conflicts of interest. None of the authors are employees of Recordati Rare Diseases Inc.
References
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Miscellaneous
